Genticel names Dr Didier Hoch, former president of Sanofi-Pasteur MSD, to its supervisory board

12-Jul-2011 - France

Genticel announced that it has appointed Dr Didier Hoch as member of the company’s supervisory board (conseil de surveillance).
Dr Hoch brings his outstanding experience of over 25 years in the pharmaceutical industry to Genticel. Dr Hoch’s successful career in the vaccine industry includes ten years as President of Sanofi-Pasteur – MSD, the joint venture of the vaccine businesses of Sanofi Aventis and Merck & Co., which launched one of the most successful vaccines ever: Gardasil, a preventive HPV vaccine. Dr Hoch is an expert in market access and launching of paradigm-shifting vaccines such as Gardasil, which transformed cervical cancer to a preventable viral disease.
Prior to his position as president of Sanofi-Pasteur MSD from 2000 until 2010, Didier Hoch was vice president Africa & Middle East at Aventis Pharma International, and before that he was deputy general manager at Rhône-Poulenc Rorer France. From 2003 until 2009 Dr Hoch was president of the European Vaccine Manufacturers Association (EVM). He is currently an independent board member of TcL Pharma/Effimune (France) and chairman of Pevion (Switzerland) In addition; Dr Hoch chairs the Biotechnology Committee of LEEM (the French pharma industry association) and is also president of the Life Science Health Committee of MEDEF (the major French industry association). He graduated in Medicine from the University of Lyon, France.
Didier Hoch will join the Genticel supervisory board, which, besides Thierry Hercend, is composed of following members: Ludovic de Meeus d'Argenteuil, vice-president of the board and co-founder, Alain Munoz, MD, representing Kurma Life Sciences, Raphael Wisniewski, investment director at Edmond de Rothschild Investment Partners (EdRIP), Olivier Martinez, PhD, investment manager at Innobio, and Beatrice Llirbat, MD, PhD, partner of Amundi Private Equity Funds Life Science.

Other news from the department people

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?